CPC C07K 14/005 (2013.01) [A61K 39/12 (2013.01); A61P 31/14 (2018.01); C07K 14/1825 (2013.01); C07K 16/1081 (2013.01); G01N 33/56983 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C12N 2770/24122 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/24171 (2013.01); Y02A 50/30 (2018.01)] | 19 Claims |
1. A composition comprising an isolated neutralizing antibody or antigen binding fragment thereof directed against a flavivirus envelope dimer epitope (EDE) and an adjuvant,
wherein the antibody or fragment comprises six CDRs wherein each CDR comprises an amino acid sequence selected from the group consisting of:
SEQ ID Nos: 15 to 26 and sequences with no more than 30% modification from any one of said SEQ ID No. 15 to 26,
wherein:
(a) said antibody or fragment thereof binds the five polypeptide segments of the dengue virus glycoprotein E ectodomain (sE) consisting of the residues 67-74, residues 97-106, residues 307-314, residues 148-159 and residues 243-251, or corresponding residues of the flavivirus or Zika virus glycoprotein E ectodomain, or consisting of Zika PF13 residues 67-77, residues 97-106, residues 313-315, residues 243-253, residue K373 or corresponding residues of the flavivirus glycoprotein E ectodomain, or
(b) binding is unaffected by presence or absence of dengue N153 (Zika N154) glycan or corresponding residue.
|